Literature DB >> 8067756

Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages.

N Mor1, J Vanderkolk, L Heifets.   

Abstract

Levofloxacin exhibited twofold greater inhibitory and bactericidal activities than ofloxacin against either extracellular or intracellular tubercle bacilli. The activities of both drugs against extracellular and intracellular bacteria were about the same, despite the accumulation of the drugs in macrophages at a level four- to fivefold greater than that in the extracellular medium. The activities of both drugs against intracellular bacteria were largely associated with the short, 2-h pulsed exposures of the infected macrophages to the concentrations which correspond to those attainable in blood during the period of the maximum concentration of drug in serum.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8067756      PMCID: PMC188169          DOI: 10.1128/AAC.38.5.1161

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  [In vitro activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis, M. avium, M. africanum, M. kansasii and BCG strains].

Authors:  L Thomas; P Naumann; A Crea
Journal:  Immun Infekt       Date:  1986-11

2.  In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis.

Authors:  O G Berlin; L S Young; D A Bruckner
Journal:  J Antimicrob Chemother       Date:  1987-05       Impact factor: 5.790

3.  [In vitro and in vivo activities of norfloxacin, ofloxacin and ciprofloxacin against various mycobacteria].

Authors:  H Saito; K Sato; H Tomioka; T Watanabe
Journal:  Kekkaku       Date:  1987-05

4.  MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages.

Authors:  N Mor; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

5.  Preliminary demonstration of human tuberculoimmunity in vitro.

Authors:  A J Crowle; M May
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

6.  Comparative in-vitro activity of five fluoroquinolones against mycobacteria.

Authors:  S Davies; P D Sparham; R C Spencer
Journal:  J Antimicrob Chemother       Date:  1987-05       Impact factor: 5.790

7.  Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria.

Authors:  L S Young; O G Berlin; C B Inderlied
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

8.  The pharmacokinetics and tissue penetration of ofloxacin.

Authors:  M R Lockley; R Wise; J Dent
Journal:  J Antimicrob Chemother       Date:  1984-12       Impact factor: 5.790

9.  In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL8280).

Authors:  M Tsukamura
Journal:  Am Rev Respir Dis       Date:  1985-03

10.  Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare.

Authors:  C H Fenlon; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

View more
  22 in total

Review 1.  New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development.

Authors:  Masayuki Igarashi; Yoshimasa Ishizaki; Yoshiaki Takahashi
Journal:  J Antibiot (Tokyo)       Date:  2017-11-01       Impact factor: 2.649

2.  Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells.

Authors:  A Pascual; I García; S Ballesta; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 3.  Susceptibility testing of Mycobacterium avium complex isolates.

Authors:  L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

Review 4.  Future directions in the development of new antitubercular drugs. Where do we go from here?

Authors:  W W Yew; C H Chau
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

5.  Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages.

Authors:  N Mor; B Simon; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

6.  Increased Vancomycin Susceptibility in Mycobacteria: a New Approach To Identify Synergistic Activity against Multidrug-Resistant Mycobacteria.

Authors:  Karine Soetaert; Céline Rens; Xiao-Ming Wang; Jacqueline De Bruyn; Marie-Antoinette Lanéelle; Françoise Laval; Anne Lemassu; Mamadou Daffé; Pablo Bifani; Véronique Fontaine; Philippe Lefèvre
Journal:  Antimicrob Agents Chemother       Date:  2015-06-01       Impact factor: 5.191

7.  Roxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige mice.

Authors:  L E Bermudez; P Kolonoski; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

8.  Activities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice.

Authors:  L E Bermudez; C B Inderlied; P Kolonoski; M Wu; L Barbara-Burnham; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

9.  Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of Mycobacterium avium.

Authors:  N Mor; J Vanderkolk; N Mezo; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

10.  Activity of levofloxacin in a murine model of tuberculosis.

Authors:  S P Klemens; C A Sharpe; M C Rogge; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.